학술논문
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
Document Type
Article
Author
Stuart, A.S.V.; Shaw, R.H.; Liu, X.; Greenland, M.; Aley, P.K.; Clutterbuck, E.A.; Dinesh, T.; Horsington, B.M.; Lambe, T.; Mujadidi, Y.F.; Plested, E.L.; Provstgaard-Morys, S.; Ramasamy, M.N.; Robinson, H.; Singh, N.; Vichos, I.; White, R.; Snape, M.D.; Screaton, G.R.; Andrews, N.J.; Ramsay, M.; Cameron, J.C.; Charlton, S.; England, A.; Hallis, B.; Collins, A.M.; Ferreira, D.M.; Hill, H.; Darton, T.; Payne, R.; Duncan, C.J.A.; Faust, S.N.; Read, R.C.; Finn, A.; Goodman, A.L.; Green, C.A.; Heath, P.T.; Lazarus, R.; Libri, V.; Lillie, P.J.; Turner, D.P.J.; Turner, P.J.; Nguyen-Van-Tam, J.S.
Source
In: The Lancet . (The Lancet, 1 January 2022, 399(10319):36-49)
Subject
Language
English
ISSN
1474547X
01406736
01406736